<SEC-DOCUMENT>0001999371-24-004298.txt : 20240401
<SEC-HEADER>0001999371-24-004298.hdr.sgml : 20240401
<ACCEPTANCE-DATETIME>20240401163516
ACCESSION NUMBER:		0001999371-24-004298
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20240401
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240401
DATE AS OF CHANGE:		20240401

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Tonix Pharmaceuticals Holding Corp.
		CENTRAL INDEX KEY:			0001430306
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				261434750
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36019
		FILM NUMBER:		24810022

	BUSINESS ADDRESS:	
		STREET 1:		26 MAIN STREET, SUITE 101
		CITY:			CHATHAM
		STATE:			NJ
		ZIP:			07928
		BUSINESS PHONE:		212-980-9155

	MAIL ADDRESS:	
		STREET 1:		26 MAIN STREET, SUITE 101
		CITY:			CHATHAM
		STATE:			NJ
		ZIP:			07928

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TAMANDARE EXPLORATIONS INC.
		DATE OF NAME CHANGE:	20080320
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tnxp_8k-040124.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:TNXP="http://TNXP/20240401">
<head>
     <title>Current Report</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_038_TNXP_TNXP_20240401 -->
<!-- Field: Set; Name: xdx; ID: xdx_04D_20240401_20240401 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05B_edei%2D%2DEntityCentralIndexKey_0001430306 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body>
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2024-04-01" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-04-01" id="Fact000004" name="dei:EntityCentralIndexKey">0001430306</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="tnxp-20240401.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2024-04-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-04-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 1pt Times New Roman,serif; margin: 0">&#160;</p>



<!-- Field: Rule-Page --><div style="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Arial,sans-serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Arial,sans-serif; margin: 0; text-align: center"></p>

<p style="font: 14pt Times New Roman,serif; margin: 0; text-align: center"><b>UNITED STATES </b></p>

<p style="font: 14pt Times New Roman,serif; margin: 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION </b></p>

<p style="font: 12pt Times New Roman,serif; margin: 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Arial,sans-serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 1pt Arial,sans-serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 18pt Times New Roman,serif; margin: 0; text-align: center"><b>FORM <span id="xdx_905_edei--DocumentType_c20240401__20240401_zKTSf5XqR6dh"><ix:nonNumeric contextRef="AsOf2024-04-01" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 12pt Times New Roman,serif; margin: 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 12pt Times New Roman,serif; margin: 0; text-align: center"><b>Pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><b>Date of report (date of earliest event reported): <span id="xdx_902_edei--DocumentPeriodEndDate_c20240401__20240401_zUSjxgMeDQD1"><ix:nonNumeric contextRef="AsOf2024-04-01" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">April
1, 2024</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 1pt Arial,sans-serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 24pt Times New Roman,serif; margin: 0; text-align: center"><b><span id="xdx_909_edei--EntityRegistrantName_c20240401__20240401_zoocl1ICvgZg"><ix:nonNumeric contextRef="AsOf2024-04-01" id="Fact000011" name="dei:EntityRegistrantName">TONIX PHARMACEUTICALS HOLDING CORP.</ix:nonNumeric></span></b>&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><b>(Exact name of registrant as specified in its charter)</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman,serif; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_900_edei--EntityIncorporationStateCountryCode_c20240401__20240401_zgmX51X6M969"><ix:nonNumeric contextRef="AsOf2024-04-01" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></b></span></td>
    <td style="font: 12pt Times New Roman,serif; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_904_edei--EntityFileNumber_c20240401__20240401_zQk6SPozyaGk"><ix:nonNumeric contextRef="AsOf2024-04-01" id="Fact000013" name="dei:EntityFileNumber">001-36019</ix:nonNumeric></span></b></span></td>
    <td style="font: 12pt Times New Roman,serif; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_903_edei--EntityTaxIdentificationNumber_c20240401__20240401_z526KGUXnao9"><ix:nonNumeric contextRef="AsOf2024-04-01" id="Fact000014" name="dei:EntityTaxIdentificationNumber">26-1434750</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td>
    <p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><b>(State or Other Jurisdiction </b></p>
    <p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><b>of Incorporation) </b></p></td>
    <td>
    <p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><b>(Commission </b></p>
    <p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><b>File Number)</b></p></td>
    <td>
    <p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><b>(IRS Employer </b></p>
    <p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><b>Identification No.)</b>&#160;</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><span id="xdx_908_edei--EntityAddressAddressLine1_c20240401__20240401_z2khVDygDha5"><ix:nonNumeric contextRef="AsOf2024-04-01" id="Fact000015" name="dei:EntityAddressAddressLine1">26 Main Street</ix:nonNumeric></span>, <span id="xdx_90B_edei--EntityAddressCityOrTown_c20240401__20240401_zau4subSlso9"><ix:nonNumeric contextRef="AsOf2024-04-01" id="Fact000016" name="dei:EntityAddressCityOrTown">Chatham</ix:nonNumeric></span>, <span id="xdx_908_edei--EntityAddressStateOrProvince_c20240401__20240401_ziygbSZtvtm8"><ix:nonNumeric contextRef="AsOf2024-04-01" format="ixt-sec:stateprovnameen" id="Fact000017" name="dei:EntityAddressStateOrProvince">New Jersey</ix:nonNumeric></span> <span id="xdx_908_edei--EntityAddressPostalZipCode_c20240401__20240401_zyAic9fBAOw4"><ix:nonNumeric contextRef="AsOf2024-04-01" id="Fact000018" name="dei:EntityAddressPostalZipCode">07928</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><b>(Address of principal executive offices) (Zip Code)</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><b>Registrant&#8217;s telephone number, including area code:</b>
<span id="xdx_906_edei--CityAreaCode_c20240401__20240401_zwBzPjfDVr7k"><ix:nonNumeric contextRef="AsOf2024-04-01" id="Fact000019" name="dei:CityAreaCode">(862)</ix:nonNumeric></span> <span id="xdx_90D_edei--LocalPhoneNumber_c20240401__20240401_zHdZ4KcUcNH8"><ix:nonNumeric contextRef="AsOf2024-04-01" id="Fact000020" name="dei:LocalPhoneNumber">904-8182</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><span style="font-family: Segoe UI Symbol,sans-serif"><span id="xdx_90E_edei--WrittenCommunications_c20240401__20240401_zgRvgGus82sd"><ix:nonNumeric contextRef="AsOf2024-04-01" format="ixt:booleanfalse" id="Fact000021" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span>
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><span style="font-family: Segoe UI Symbol,sans-serif"><span id="xdx_902_edei--SolicitingMaterial_c20240401__20240401_zb7YKZQVrs7e"><ix:nonNumeric contextRef="AsOf2024-04-01" format="ixt:booleanfalse" id="Fact000022" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span>
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><span style="font-family: Segoe UI Symbol,sans-serif"><span id="xdx_907_edei--PreCommencementTenderOffer_c20240401__20240401_zliHy588ipXg"><ix:nonNumeric contextRef="AsOf2024-04-01" format="ixt:booleanfalse" id="Fact000023" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span>
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><span style="font-family: Segoe UI Symbol,sans-serif"><span id="xdx_90A_edei--PreCommencementIssuerTenderOffer_c20240401__20240401_zBTwCiGmaej3"><ix:nonNumeric contextRef="AsOf2024-04-01" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span>
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white">Securities registered pursuant to
Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="2" style="width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border: black 1pt solid; font: 12pt Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">Title of each class</span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 12pt Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">Trading Symbol(s)</span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 12pt Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">Name of each exchange on which registered</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 12pt Times New Roman,serif; text-align: justify"><span style="font-size: 10pt"><span id="xdx_90A_edei--Security12bTitle_c20240401__20240401_zHwoktl825A"><ix:nonNumeric contextRef="AsOf2024-04-01" id="Fact000025" name="dei:Security12bTitle">Common Stock</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 12pt Times New Roman,serif; text-align: justify"><span style="font-size: 10pt"><span id="xdx_902_edei--TradingSymbol_c20240401__20240401_zU9zA2iDhf75"><ix:nonNumeric contextRef="AsOf2024-04-01" id="Fact000026" name="dei:TradingSymbol">TNXP</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 12pt Times New Roman,serif; text-align: justify">The <span style="font-size: 10pt"><span id="xdx_90F_edei--SecurityExchangeName_c20240401__20240401_zNl9gmTPpki"><ix:nonNumeric contextRef="AsOf2024-04-01" format="ixt-sec:exchnameen" id="Fact000027" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span></span> Capital Market</td></tr>
  </table>
<p style="font: 1pt Times New Roman,serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white">Indicate by check mark whether the
registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule
12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</p>

<p style="font: 10pt Arial,sans-serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white">Emerging growth company <span style="font-family: Segoe UI Symbol,sans-serif"><span id="xdx_901_edei--EntityEmergingGrowthCompany_c20240401__20240401_zh9Bw2Na98Id"><ix:nonNumeric contextRef="AsOf2024-04-01" format="ixt:booleanfalse" id="Fact000028" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white">If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Segoe UI Symbol,sans-serif">&#9744;</span>&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white"></p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 4pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->




<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->


<p style="font: 12pt Times New Roman,serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman,serif; width: 15%"><span style="font-size: 10pt"><b>Item 2.02</b></span></td>
    <td style="font: 12pt Times New Roman,serif; width: 85%"><span style="font-size: 10pt"><b>Results of Operations and Financial Condition</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 12pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On April
1, 2024, Tonix Pharmaceuticals Holding Corp. (the &#8220;Company&#8221;) announced its operating results for the quarter and year ended
December 31, 2023. A copy of the press release that discusses these matters is filed as Exhibit 99.01 to, and incorporated by reference
in, this report.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman,serif; width: 15%"><span style="font-size: 10pt"><b>Item 9.01</b></span></td>
    <td style="font: 12pt Times New Roman,serif; width: 85%"><span style="font-size: 10pt"><b>Financial Statements and Exhibits.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tr>
    <td style="font: 12pt Times New Roman,serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt">(d)</span></td>
    <td style="font: 12pt Times New Roman,serif; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">
    <p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><b>Exhibit</b></p>
    <p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><b>No.</b></p></td>
    <td style="font: 12pt Times New Roman,serif; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="border-bottom: black 1pt solid; font: 12pt Times New Roman,serif; vertical-align: bottom; text-align: center"><span style="font-size: 10pt"><b>Description.</b></span></td></tr>
  <tr>
    <td style="font: 12pt Times New Roman,serif; vertical-align: top; text-align: justify">&#160;</td>
    <td style="font: 12pt Times New Roman,serif; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center; color: #0000EE"><span style="text-decoration: underline"><a href="ex99-01.htm">99.01</a></span></p>
    <p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center">104</p></td>
    <td style="font: 12pt Times New Roman,serif; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman,serif; margin: 0">Press release of the Company, dated April 1, 2024</p>
    <p style="font: 10pt Times New Roman,serif; margin: 0">Cover Page Interactive Data File (embedded within the Inline XBRL document)</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><b>&#160;</b></p>


<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman,serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><b>SIGNATURE</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirement of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 12pt">
  <tr style="vertical-align: bottom">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td colspan="3" style="font-family: Times New Roman,serif"><span style="font-size: 10pt"><b>TONIX PHARMACEUTICALS HOLDING CORP.</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td colspan="3" style="font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-family: Times New Roman,serif; width: 50%"><span style="font-size: 10pt">Date: April 1, 2024</span></td>
    <td style="font-family: Times New Roman,serif; width: 5%"><span style="font-size: 10pt">By: </span></td>
    <td style="border-bottom: black 1pt solid; font-family: Times New Roman,serif; width: 40%"><span style="font-size: 10pt">/s/ Bradley Saenger</span></td>
    <td style="font-family: Times New Roman,serif; width: 5%">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td colspan="3" style="font-family: Times New Roman,serif"><span style="font-size: 10pt">Bradley Saenger</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td colspan="3" style="font-family: Times New Roman,serif"><span style="font-size: 10pt">Chief Financial Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0">&#160;</p>

<p style="font: 12pt Times New Roman,serif; margin: 0; text-align: center">&#160;</p>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 12pt Times New Roman,serif; margin: 0; text-align: center"></p>


<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KgkAQhZ/Adxj2WkoXg/CuxCSyCInodskxlnRHZre/R+ot25RoGBiGc75zhAhFQSvdIsNpWZVwwK5vlUOosEFGc0bvyNabFPyt8KKtY2Xc8P7AjDyDnplNpFReGKx3bbFOIUqmUTyVCcQync1hsRXBV8/INLpG47RqQZka9kw9a3SKX2PCQT3JUPcaqo7IVpNJIZ5Eo/wGGcUSdnRXD+KrhbLMRBAOE4iC6dZ7V/50aL4k5C12vs6O9H+DD/4BSn4= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.01
<SEQUENCE>2
<FILENAME>ex99-01.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 8pt; text-align: right; text-indent: 0.5in"><B>Exhibit 99.01</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 8pt; text-align: center; text-indent: 0.5in"><B>Tonix Pharmaceuticals
Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>Positive results from confirmatory Phase 3 RESILIENT
study reported in December 2023 position Tonmya&trade; for fibromyalgia for NDA submission second half of 2024; pre-NDA meeting with FDA
scheduled for second quarter 2024</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>Commercial planning underway, including go-to-market,
supply chain and manufacturing strategies, for U.S. launch of Tonmya, a potential new first-line, centrally-acting, non-opioid analgesic
for the management of fibromyalgia</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #FF9966">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">CHATHAM, N.J., April 1, 2024 (GLOBE NEWSWIRE) &ndash;
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed
products and a pipeline of development candidates, today announced financial results for the fourth quarter and full year ended December
31, 2023, and provided an overview of recent operational highlights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #FF9966">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&ldquo;Our near-term focus is seeking U.S. marketing
approval for Tonmya (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia from the U.S. Food and Drug Administration
(FDA),&rdquo; said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. &ldquo;Our pre-NDA meeting with the FDA is scheduled
to take place this quarter and we plan to submit our New Drug Application (NDA) for Tonmya&trade; in the second half of 2024. We believe
the positive Phase 3 RESILIENT results reported in December of 2023 together with the positive results from the first Phase 3 RELIEF study
should satisfy the requirements for approval and, if so, would provide the opportunity for Tonix to launch the first FDA-approved drug
for fibromyalgia in more than a decade. We believe the activity of Tonmya on improving pain, sleep quality, fatigue and brain fog in the
RESILIENT study are indicative of the broad-spectrum of activity in fibromyalgia.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Dr. Lederman added, &ldquo;While Tonix is focusing
its resources on progressing Tonmya toward NDA submission and potential FDA approval, we are seeking partnerships and collaborations on
our pipeline programs from government agencies, non-profit organizations and other biotechnology or pharmaceuticals companies. Tonix has
already shifted portions of our research and development (R&amp;D) expenses to U.S. government agencies and other institutions through
partnerships involving grants and in-kind contributions. These outside collaborations leverage our internal resources, and we believe
they provide a capital efficient strategy for progress.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>Selected Product Candidates* -- Recent Highlights
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><I><U>Central Nervous System (CNS) Pipeline</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><I>Tonmya (also known as TNX-102 SL; cyclobenzaprine
HCl sublingual tablets): a centrally-acting, non-opioid, small molecule analgesic taken once-daily at bedtime for the management of fibromyalgia
(FM).</I></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">The Company announced in December 2023 that the Phase 3 RESILIENT study, a registration-quality, double-blind,
placebo-controlled study evaluating TNX-102 SL met its pre-specified primary endpoint in the second of two positive Phase 3 clinical trials,
significantly reducing daily pain compared to placebo (p=0.00005) in participants with fibromyalgia. Statistically significant and clinically
meaningful results were also seen in all key secondary endpoints related to improving sleep quality, reducing fatigue, and improving patient
global ratings and overall fibromyalgia symptoms and function. Additionally, as it relates to improving daily pain, treatment with TNX-102
SL showed a robust and clinically meaningful analgesic Cohen&rsquo;s <I>d</I> effect size of 0.38, with rapid onset of action, separating
from placebo for every week of the study. TNX-102 SL was well tolerated with an adverse event profile comparable to prior studies and
no new safety signals observed. Tonix plans to submit an NDA to the FDA in the second half of 2024 for TNX-102 SL for the management of
fibromyalgia.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">In January 2024, Tonix presented additional safety and tolerability data from the Phase 3 RESILIENT study
that showed TNX-102 SL treatment was not associated with increases in systolic or diastolic blood pressure or body weight, nor were there
any reported sexual side effects.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">In January 2024, Tonix announced that the FDA has conditionally accepted the trade name, Tonmya, for the
Company&rsquo;s drug product candidate TNX-102 SL for the management of fibromyalgia.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">In February 2024, Tonix announced positive results from its clinical pharmacokinetic (PK) bridging study
of Tonmya in healthy adult male and female ethnic Japanese and Chinese volunteers. Results indicate that key PK parameters of cyclobenzaprine
are comparable in ethnic Japanese and Chinese volunteers to Caucasian volunteers from a prior PK study. Tonmya was generally well tolerated
in the ethnic Japanese and Chinese healthy volunteers. The company expects these data to fulfill the requirement for a bridging study,
and enables Tonix to rely on Phase 3 studies RESILIENT and RELIEF results to support regulatory filings for clinical studies in Japan
and China where cyclobenzaprine is a new chemical entity (NCE). Tonix holds issued patents for market exclusivity rights of Tonmya in
Japan, China, Hong Kong and Taiwan.</TD></TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">In February 2024, Tonix selected Rho, Inc., a global contract research organization, to support Tonix&rsquo;s
preparation and planned submission of its NDA to the FDA for the approval of Tonmya for the management of fibromyalgia.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">In March 2024, Tonix announced the selection of two CMOs, including Almac Pharma Services, as dual supply
sources for the potential launch and commercialization of Tonmya in the U.S.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">In March 2024, Tonix selected EVERSANA, a leading provider of commercialization services to the global
life sciences industry, to support the launch strategy and commercial planning of Tonmya in the U.S.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Tonix presented additional efficacy data from RESILIENT at the 6<SUP>th</SUP> International Congress on
Controversies in Fibromyalgia in Brussels, Belgium, March 7-8, 2024. The data showed that Tonmya treatment resulted in an improvement
in cognitive dysfunction, or &lsquo;brain fog&rsquo;, measured by the change in the Fibromyalgia Impact Questionnaire-Revised (FIQ-R)
memory item. The FIQ-R cognitive item showed nominal improvement in Tonmya-treated patients vs placebo-treated patients with <I>p-value</I>=0.001
and effect size of 0.31.</TD></TR></TABLE>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 8pt; text-align: justify"><I>TNX-102 SL for the treatment of acute
stress reaction (ASR) and acute stress disorder (ASD), and prophylaxis against development of posttraumatic stress disorder (PTSD)</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">In February 2024, the Company announced the FDA cleared the Investigational New Drug (IND) application
for the Phase 2 investigator-initiated OASIS trial to evaluate TNX-102 SL in reducing the severity of ASR and the frequency of ASD and
PTSD. The trial is sponsored by The UNC Institute for Trauma Recovery and supported by a $3 million grant from the U.S. Department of
Defense (DoD), which was awarded in September 2023. The proposed Phase 2, Optimizing Acute Stress Reaction Interventions with TNX-102
SL (OASIS) study will examine the safety and efficacy of TNX-102 SL to reduce adverse posttraumatic neuropsychiatric sequelae among patients
presenting to the emergency department (ED) after a motor vehicle collision (MVC). The study will enroll approximately 180 trauma survivors
at ED study sites in the U.S. Participants will be randomized in the ED to receive a two-week course of either TNX-102 SL 5.6 mg or placebo.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Tonix expects the Phase 2 OASIS trial will initiate in the second quarter of 2024.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 8pt; text-align: justify"><I>TNX-102 SL for the treatment of Fibromyalgia-Type
Long COVID, also known as Post-Acute Sequelae of COVID-19 (PASC)</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">In January 2024, the Company announced the online publication of a research paper in the Journal <I>Pain.
</I>The article titled, &ldquo;Chronic Overlapping Pain Conditions Increase the Risk of Long COVID Features, Regardless of Acute COVID
Status,&rdquo; by Bergmans,&nbsp;et al.<SUP>&nbsp;1</SUP>, found that patients with pre-existing chronic overlapping pain conditions (COPCs)
had an increased risk of being diagnosed with symptoms of Long COVID<SUP>1</SUP>. Faculty at the University of Michigan directed the research.
Commentary on the article titled, &ldquo;A step towards better understanding chronic overlapping pain conditions&rdquo; by Fitzcharles,&nbsp;et
al,<SUP>2</SUP>&nbsp;is in the same issue of the journal. COPCs include fibromyalgia, chronic fatigue syndrome, migraine headache, irritable
bowel syndrome, endometriosis and low back pain. These results contribute to a growing body of evidence that common symptoms of Long COVID
in many patients are at least partly driven by central nervous system mechanisms.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">In September 2023, the Company reported topline results from its Phase 2 PREVAIL proof-of-concept study
of TNX-102 SL for fibromyalgia-type Long COVID. TNX-102 SL showed a robust Cohen&rsquo;s <I>d</I> effect size of 0.50 in improving fatigue
relative to placebo; and it showed consistent activity across secondary measures of sleep quality, cognitive function, disability and
Patient Global Impression of Change, but did not meet the primary endpoint of multi-site pain reduction at Week 14. TNX-102 SL was generally
well tolerated and no new safety signals were observed. The Company intends to request an End-of-Phase 2 meeting with the FDA to discuss
a potential Phase 3 program based on a proposed primary outcome measure using the PROMIS Fatigue scale.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><I>TNX-1300 (recombinant double mutant cocaine
esterase): biologic for life-threatening cocaine intoxication</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Tonix expects to initiate a Phase 2 clinical study of TNX-1300 for the treatment of cocaine intoxication
in emergency rooms in the second quarter of 2024. In 2022, Tonix was awarded a Cooperative Agreement grant from the National Institutes
of Health (NIH)&rsquo;s National Institute of Drug Abuse (NIDA) to support development of TNX-1300.</TD></TR></TABLE>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">TNX-1300 has been granted Breakthrough Therapy designation by the FDA.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><I>TNX-1900 (intranasal potentiated oxytocin):
small peptide in development through investigator-initiated studies for bone health in autism, social anxiety disorder (SAD), adolescent
obesity and binge eating disorder</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">In November 2023, Tonix announced that the first participant was enrolled in an investigator-initiated
Phase 2 study of TNX-1900 for improving bone health in children with autism spectrum disorder, named the BOX study, at Massachusetts General
Hospital (MGH). The aim of this DoD funded study is to investigate the efficacy and safety of TNX-1900 as a novel therapeutic agent to
increase bone density and improve bone structure and strength in children with autism spectrum disorder. Tonix is providing active drug
and placebo for the BOX study as part of a drug donation agreement with MGH. MGH is the sponsor of the trial, which is being conducted
under an investigator-initiated IND application.</TD></TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">TNX-1900 is also being studied in three other ongoing investigator-initiated Phase 2 studies as follows:</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">MGH Phase 2 study for binge-eating disorder (BED)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">University of Washington Phase 2 study for social anxiety disorder (SAD)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">MGH Phase 2 study for adolescent obesity</TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><I><U>Rare Disease Pipeline</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><I>TNX-2900 (intranasal potentiated oxytocin):
small peptide for the treatment of Prader-Willi syndrome (PWS)</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">In December 2023, Tonix announced that the FDA has cleared the IND application to support clinical development
of TNX-2900 to treat PWS in children and adolescents. The Phase 2 study approved under the IND is a dose-finding study involving approximately
36 PWS patients divided into four groups with approximately nine per group. One group will receive placebo and three groups will receive
different dosage regimens of TNX-2900. TNX-2900 for the treatment of PWS was granted Orphan Drug designation by the FDA in 2022.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0 0.25in; text-align: justify"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">In March 2024, Tonix announced that it received Rare Pediatric Disease designation from the FDA for TNX-2900
for the treatment of PWS.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><I><U>Immunology Pipeline</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><I>TNX-1500 (anti-CD40L Fc-modified humanized
monoclonal antibody): third generation anti-CD40L monoclonal antibody for prophylaxis of organ transplant rejection and treatment of autoimmune
disorders.</I></P>




<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">The first indication for TNX-1500 is prophylaxis of organ rejection in adult patients receiving a kidney
transplant; but multiple additional indications are possible, including autoimmune diseases. Two peer reviewed publications described
the work at the Massachusetts General Hospital (MGH) on allogeneic transplants in animals were published.<SUP>3,4</SUP></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Preclinical studies have shown that TNX-1500 maintains the activity of first-generation monoclonal antibodies
(mAbs), yet with reduced risk of thrombotic complications.<SUP>3-5</SUP> Modeling studies from animal pharmacokinetic data<SUP>3</SUP>
predict a half-life of approximately three weeks for TNX-1500 in humans, which supports a monthly <I>i.v.</I> dosing regimen. This analysis
together with TNX-1500&rsquo;s activity and tolerability in animals, suggests that the protein engineering of TNX-1500&rsquo;s Fc region
has achieved its design goals.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">In October 2023, the Company announced data from two oral presentations delivered at medical meetings
in 2023. The oral presentations titled, &ldquo;<I>Pilot Evaluation of a Clinical Xeno Heart Transplant Regimen in a Preclinical Model</I>&rdquo;
and &ldquo;<I>Extended Survival of 9- and 10-Gene Edited Pig Heart Xenografts with Ischemia Minimization and CD154 Costimulation Blockade-Based
Immunosuppression</I>&rdquo; by Dr. Ikechukwu Ileka&nbsp;<I>et al</I>. include data demonstrating the use of TNX-1500 as maintenance therapy
after xenogeneic heart transplant in non-human primates. In both studies, genetically engineered (GE) pigs in baboon transplants were
treated with cold-perfused ischemia minimization and a novel costimulation-based immunosuppressive regimen that includes TNX-1500.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">In October 2023, Tonix announced that a study published in the Journal&nbsp;<I>Nature</I><SUP>5</SUP>&nbsp;by
faculty at the Center for Transplantation Sciences, MGH, in collaboration with biotechnology company, eGenesis, utilized TNX-1500 as part
of the immune modulating regimen to prevent organ transplant rejection. The&nbsp;<I>Nature</I>&nbsp;article titled, &ldquo;<I>Design and
testing of a humanized porcine donor for xenotransplantation</I>&rdquo; includes data that provide additional support for TNX-1500&rsquo;s
activity in preventing pig xenograft organ rejection and for its safety and tolerability in non-human primates.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">In February 2024, Tonix announced the completion of the clinical stage of its Phase 1 single ascending
dose study of TNX-1500 in healthy volunteers. The primary objectives of the study are to assess the safety, tolerability, pharmacokinetics
and pharmacodynamics of intravenous TNX-1500. Topline results are expected in the third quarter of 2024. This first-in-human study is
intended to support dosing in a planned Phase 2 trial in kidney transplant recipients.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">In March of 2024, the MGH announced the first transplant of a genetically modified pig kidney into a living
patent in collaboration with eGenesis, which produced the pig donors.<SUP>6</SUP> Some of the pre-clinical work that supported this transplant
was performed in collaboration with Tonix and used TNX-1500.<SUP>5</SUP></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><I><U>Infectious Disease Pipeline</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><I>TNX-1800 (modified recombinant horsepox
virus, live vaccine): potential vaccine to protect against COVID-19 designed to express the SARS-CoV-2 spike protein</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Results from a study with our TNX-1800 vaccine that showed animals were protected from challenge with
SARS-CoV-2 were published as an article in the peer reviewed journal, <I>Viruses</I> in 2023.<SUP>7</SUP></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0 0.25in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">In November 2023, Tonix announced that NIH and National Institute of Allergy and Infectious Diseases (NIAID)
will conduct a Phase 1 clinical trial with TNX-1800 as part of Project NextGen. NIAID will cover the full cost of the clinical trial,
including operations and related analyses. Tonix will be responsible for providing clinical trial materials, and upon completion will
have the right to rely on the findings in regulatory filings with the FDA to support the approval of its COVID-19 vaccine and other vaccines
based on the recombinant pox vaccine (RPV) platform.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">We believe the TNX-1800 vaccine development plan addresses several priority vaccine attributes advanced
by the White House Office of Science and Technology Policy&rsquo;s Pandemic Preparedness Plan,<SUP>8</SUP> the National Biodefense Science
Board<SUP>9</SUP> and BARDA.<SUP>10</SUP> Tonix believes its RPV platform can address a wide variety of disease targets of public health
interest.&nbsp;</TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><I>TNX-801 (recombinant horsepox virus, live
vaccine): potential vaccine to protect against mpox disease and smallpox.</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Results from a study with our TNX-801 vaccine that showed animals were protected from mpox were reported
at a meeting in the first quarter of 2020 and published as an article in the peer reviewed journal, <I>Viruses</I> in 2023.<SUP>11</SUP></TD></TR></TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">On December 14, 2023, Dr. Lederman participated in a panel discussion on Vaccine Research &amp; Development
at the National Academies of Sciences, Engineering, and Medicine (NAS) Committee on the Current State of Research, Development, and Stockpiling
of Smallpox Medical Countermeasures public meeting. Discussions explored lessons learned from the recent COVID-19 pandemic and mpox multi-country
outbreak to inform an evaluation of the current state of research, development, and stockpiling of smallpox readiness and response measures.
The Consensus Study Report was issued on March 28, 2024.<SUP>12</SUP> Some of the conclusions included recommendations for single dose
vaccines, safer vaccines, vaccine platforms and attention to supply chain and manufacturing. Tonix believes TNX-801 has the potential
to address some of the recommendations from the NAS Committee since it provides single dose protection to animals, and has the potential
for favorable dose, manufacturing and cold chain requirements.</TD></TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">In August 2023, Tonix received the official written response from a Type B pre-IND meeting with the FDA
to develop TNX-801&nbsp;as a potential vaccine to protect against mpox disease (formerly known as monkeypox) and smallpox. Tonix believes
the FDA feedback provides a path to agreement on the design of a Phase 1/2 study and the overall clinical development plan. The Phase
1/2 clinical trial will assess the safety, tolerability, and immunogenicity of TNX-801, following the submission and clearance of an IND.</TD></TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Concerns about current state of new smallpox and mpox vaccines in development have been raised by the
U.S. Bipartisan Commission on Biodefense<SUP>13</SUP> and by an outbreak of mpox in the Democratic Republic of the Congo.<SUP>14</SUP></TD></TR></TABLE>





<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Results from a study with our TNX-801 vaccine that showed decreased virulence relative to traditional
live vaccinia vaccine strains were posted on the website BioRxiv in 2023.<SUP>15</SUP></TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><I>Broad-spectrum anti-viral programs</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify">Tonix is developing potential broad-spectrum
antiviral drugs in three programs: CD45-targeted therapeutics (TNX-4200), cathepsin inhibitors (TNX-3900) and viral glycan-targeted engineered
biologics (TNX-4000). In 2020, the DoD announced that they are seeking broad spectrum antiviral drugs since it would be hard to predict
which or how many viruses may be deployed on the battlefield.<SUP>16</SUP> Tonix hopes that one or more of our programs may help the DoD
address that goal.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>Marketed Products &ndash; Recent Highlights</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Tonix completed the acquisition of Zembrace&reg; SymTouch&reg; (sumatriptan injection) 3 mg and Tosymra
(sumatriptan nasal spray) 10 mg from Upsher-Smith Laboratories, LLC on June 30, 2023. Both products are indicated for the treatment of
acute migraine with or without aura in adults.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Combined net product revenue of $7.8 million reported for the period July 1, 2023 &ndash; December 31,
2023 for Zembrace Symtouch and Tosymra.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">As of April 1, 2024, Tonix completed the transition to becoming a fully integrated pharmaceutical company.
Tonix Pharmaceuticals has implemented personnel, systems and contracts required to support a commercial organization and has assumed responsibility
for distribution, selling and marketing of Zembrace SymTouch and Tosymra, as well as supply chain, regulatory and quality control of the
two products.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0 0.5in; text-align: center"><B>Facilities &ndash; Recent Highlights</B></P>



<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Tonix&rsquo;s Advanced Development Center (ADC) located in the New Bedford business park in Dartmouth,
Massachusetts, is an approximately 45,000 square foot BSL-2 facility and is intended to accelerate development and clinical scale manufacturing
of live-virus vaccines and biologics to support clinical trials. Tonix has engaged CBRE, an international real estate brokerage firm,
to find a strategic partner for, or buyer of, ADC.</TD></TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Tonix&rsquo;s Research and Development Center (RDC) in Frederick, Maryland, consisting of one building
totaling approximately 48,000 square feet, conducts research on central nervous system, immunology, and infectious disease candidates.
The RDC facility is mostly biosafety level 2 (BSL-2), with some components designated BSL-3.</TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0 0.25in; text-align: justify"><I>*All of Tonix&rsquo;s product candidates
are investigational new drugs or biologics and none have been approved for any indication.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in"><SUP>&nbsp;</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in"><SUP>1</SUP> Bergmans RS, et al.&nbsp;<I>PAIN</I>. 2023. DOI:&nbsp;<FONT STYLE="color: Blue"><U>10.1097/j.pain.0000000000003110</U></FONT><SUP>.</SUP></P>




<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><SUP>2</SUP> Fitzcharles M-A, et al.&nbsp;<I>PAIN.</I>&nbsp;2023.
DOI:&nbsp;<FONT STYLE="color: Blue"><U>10.1097/j.pain.0000000000003129</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in"><SUP>3 </SUP>Lassiter G., et al.&nbsp;<I>Am J Transplantation</I>.
2023.&nbsp;<FONT STYLE="color: Blue"><U>https://doi.org/10.1016/j.ajt.2023.03.022</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><SUP>4</SUP> Miura S., et al.&nbsp;<I>Am J Transplantation</I>.
2023.&nbsp;<FONT STYLE="color: Blue"><U>https://doi.org/10.1016/j.ajt.2023.03.025</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><SUP>5</SUP> Anand, R.P., et al&nbsp;<I>Nature.</I>&nbsp;622,
393&ndash;401 (2023).&nbsp;<FONT STYLE="color: Blue"><U>https://doi.org/10.1038/s41586-023-06594-4</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in"><SUP>6</SUP> Massachusetts General Hospital press release.
March 21, 2024. &ldquo;World&rsquo;s First Genetically Edited Pig Kidney Transplant into Living Recipient Performed at Massachusetts
General Hospital.&rdquo; <FONT STYLE="color: Blue"><U>www.massgeneral.org/news/press-release/worlds-first-genetically-edited-pig-kidney-transplant-into-living-recipient</U></FONT>
(accessed March 29, 2024)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in"><SUP>7</SUP> Awasthi M, et al. 2023. <I>Vaccines</I> (Basel)
<FONT STYLE="color: #212121; background-color: white">11(11):1682. </FONT><FONT STYLE="color: Blue; background-color: white"><U>https://doi:10.3390/vaccines11111682</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in"><SUP>8</SUP> Office of Science and Technology Policy (OSTP).
American Pandemic Preparedness: Transforming Our Capabilities. September 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in"><SUP>9</SUP> National Biodefense Science Board (NBSB). Prioritization
of Product Attribute Categories to Maximize Access for Next Generation COVID-19 Vaccines and Therapeutics. August 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in"><SUP>10</SUP> BARDA Strategic Plan 2022-2026.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in"><SUP>11</SUP> <FONT STYLE="color: #212121; background-color: white">Noyce
RS, et al. <I>Viruses</I>. 2023 26;15(2):356. doi: 10.3390/v15020356</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in"><SUP>12</SUP> U.S. National Academy of Sciences. March 28,
2024. &ldquo;Consensus Study Report: Future State of Smallpox Medical Countermeasures.&rdquo; <FONT STYLE="color: Blue"><U>https://nap.nationalacademies.org/catalog/27652/future-state-of-smallpox-medical-countermeasures</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in"><FONT STYLE="background-color: white"><SUP>13 </SUP>Bipartisan
Commission on Biodefense. (2024).&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Box the Pox: Reducing the</I></FONT></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><I>Risk of Smallpox and Other Orthopoxviruses</I></FONT><FONT STYLE="background-color: white">.
Bipartisan Commission on</FONT><BR>
<FONT STYLE="background-color: white">Biodefense: Washington, DC. https://</FONT>biodefensecommission.org/reports/box-the-pox-reducing-the-risk-of-smallpox-and-other-orthopoxviruses/</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in"><SUP>14</SUP> Emanuel, G. <I>NPR</I>. March 27, 2024. &ldquo;Why
the mpox outbreak in the Democratic Republic of Congo is worrying disease docs.&rdquo; URL: <FONT STYLE="color: Blue"><U>www.npr.org/sections/goatsandsoda/2024/03/27/1239276957/mpox-outbreak-democratic-republic-of-congo-deadlier-strain</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in"><SUP>15</SUP> <FONT STYLE="background-color: white">Trefry,&nbsp;SV
et al., BioRxiv 2023.10.25.564033; doi: https://doi.org/10.1101/2023.10.25.564033</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in"><SUP>16</SUP> U.S. Department of Defense. Chemical and Biological
Defense Program. 2022. &ldquo;Approach for Research, Development, and Acquisition of Medical Countermeasure and Test Products.&rdquo;
U.S. Department of Defense. <FONT STYLE="color: Blue"><U>https://media.defense.gov/2023/Jan/10/2003142624/-1/-1/0/APPROACH-RDA-MCM-TEST-PRODUCTS.PDF</U></FONT>
(accessed March 5, 2024)</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0 0.25in; text-align: center"><B>Recent Highlights&mdash;Financial</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify">As of December 31, 2023, Tonix had approximately
$24.9 million of cash and cash equivalents, compared to $120.2 million as of December 31, 2022. Additionally, Tonix had inventory totaling
approximately $13.6 million as of December 31, 2023. Net cash used in operations was approximately $102.0 million for the full year ended
December 31, 2023, compared to $98.1 million for the same period in 2022. Net cash used by investing activities for the full year ended
December 31, 2023 was approximately $29.1 million compared to $48.1 million for the same period in 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify">In August 2022, the Company announced that
it received a Cooperative Agreement grant from the National Institute on Drug Abuse (&ldquo;NIDA&rdquo;), part of the National Institutes
of Health, to support the development of its TNX-1300 product candidate for the treatment of cocaine intoxication. During the year ended
December 31, 2023, Tonix received $2.7 million in funding as a reduction of related research and development expenses. Included in prepaid
expense and other is an additional $0.2 million that was not received until January 2024.</P>




<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify">On December 8, 2023, the Company executed a
Loan and Guaranty Agreement (the &ldquo;Loan Agreement&rdquo;) to issue a 36-month term loan (the &ldquo;Term Loan&rdquo;) in the principal
amount of $11.0 million with a maturity date of December 8, 2026 (the &ldquo;Maturity Date&rdquo;). The Term Loan was funded with an original
issue discount of 9% of the principal amount of the Term Loan, or $1.0 million, which is being amortized over the term of the debt as
an adjustment to the effective interest rate on the outstanding borrowings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify">On December 20, 2023, the Company announced
it had signed securities purchase agreements with existing healthcare-focused institutional investors for upfront gross proceeds of approximately
$30 million through a registered direct offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify">On March 28, 2024, the Company announced it
had signed securities purchase agreements with existing healthcare-focused institutional investors for upfront gross proceeds of approximately
$4.4 million through a registered direct offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify">As of April 1, 2024, there were 84,490,862
shares of Tonix Pharmaceuticals common stock outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><U>Fourth Quarter 2023 Financial Results</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify">Net product revenue for the fourth quarter
2023 was approximately $3.8 million. Cost of Sales for the fourth quarter 2023 was approximately $2.4 million. Tonix completed the acquisition
of two currently marketed products from Upsher-Smith Laboratories, LLC on June 30, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify">R&amp;D expenses for the fourth quarter 2023
were approximately $17.1 million, compared to $24.7 million for the same period in 2022. This decrease is predominantly due to decreased
non-clinical and manufacturing expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify">SG&amp;A expenses for the fourth quarter 2023
were $11.6 million, compared to $8.1 million for the same period in 2022. The increase was primarily due to sales and marketing and the
transition services expenses associated with the Company&rsquo;s recently acquired marketed products offset by a decrease in compensation-related
expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify">Net loss available to common stockholders was
$27.3 million, or $0.86 per share, basic and diluted, for the fourth quarter 2023, compared to net loss available to common stockholders
of $34.1 million, or $3.42 per share, basic and diluted, for the same period in 2022. The basic and diluted weighted average common shares
outstanding for the fourth quarter 2023 was 31,756,759 compared to 9,952,780 shares for the same period in 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><U>Full Year 2023 Financial Results</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify">Net product revenue for the full year 2023
was approximately $7.8 million. Cost of sales for the full year 2023 was approximately $4.7 million.</P>




<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify">R&amp;D expenses for the full year 2023 were
approximately $86.7 million, compared to $81.9 million for the same period in 2022. This increase is predominantly due to decreased non-clinical
and regulatory expenses, offset by an increase in clinical, manufacturing, employee-related and professional expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify">SG&amp;A expenses for the full year 2023 were
$34.8 million, compared to $30.2 million for the same period in 2022. The increase was primarily due to sales and marketing associated
with the Company&rsquo;s recently acquired marketed products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify">Net loss available to common stockholders was
$116.7 million, or $6.85 per share, basic and diluted, for the full year 2023, compared to net loss available to common stockholders of
$116.9 million, or $20.01 per share, basic and diluted, for the same period in 2022. The basic and diluted weighted average common shares
outstanding for the full year 2023 was 17,039,309 compared to 5,841,447 shares for the same period in 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><B>Tonix Pharmaceuticals Holding Corp.<SUP>*</SUP></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify">Tonix is a biopharmaceutical company focused on developing,
licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix&rsquo;s development portfolio
is focused on central nervous system (CNS) disorders. Tonix&rsquo;s priority is to submit a New Drug Application (NDA) to the FDA in the
second half of 2024 for Tonmya, a product candidate for which two positive Phase 3 studies have been completed for the management of fibromyalgia.
TNX-102 SL is also being developed to treat acute stress reaction as well as fibromyalgia-type Long COVID. Tonix&rsquo;s CNS portfolio
includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has Breakthrough Therapy designation. Tonix&rsquo;s
immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500,
which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection
and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious
disease. Tonix Medicines, our commercial subsidiary, markets Zembrace&reg; SymTouch&reg; (sumatriptan injection) 3 mg and Tosymra&reg;
(sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">*Tonix&rsquo;s product development candidates are
investigational new drugs or biologics and have not been approved for any indication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Zembrace SymTouch and Tosymra are registered trademarks
of Tonix Medicines. All other marks are property of their respective owners.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This press release and further information about
Tonix can be found at <FONT STYLE="color: blue"><U>www.tonixpharma.com</U></FONT><FONT STYLE="font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><B>Forward Looking Statements</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times; margin: 0 0 8pt">Certain statements in this press release are forward-looking within the meaning of the
Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as &ldquo;anticipate,&rdquo;
&ldquo;believe,&rdquo; &ldquo;forecast,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; and &ldquo;intend,&rdquo; among others. These
forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of
factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include,
but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks
related to the failure to successfully market any of our products; risks related to the timing and progress of clinical development of
our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government
or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition.
As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization
of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk
factors set forth in the Annual Report as filed with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) and periodic reports
filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors
and other cautionary statements. The information set forth herein speaks only as of the date thereof.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><BR STYLE="clear: both">
</B></FONT></P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>TONIX PHARMACEUTICALS HOLDING CORP.</B>&nbsp;<BR>
<B>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</B><BR>
<B>(In Thousands, Except Share and Per Share Amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT>&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" SUMMARY="xdx: Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Year Ended<BR>
December 31,</B></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Three Months Ended<BR>
December 31,</B></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2023</B></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2022</B></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2023</B></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2022</B></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; width: 39%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">REVENUE:</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 13%; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 13%; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 13%; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 9%; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; background-color: #CCEEFF"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product revenue, net</FONT></TD>
    <TD STYLE="vertical-align: top; background-color: #CCEEFF">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; background-color: #CCEEFF">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; background-color: #CCEEFF"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; background-color: #CCEEFF; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,768</FONT></TD>
    <TD STYLE="vertical-align: bottom; background-color: #CCEEFF">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; background-color: #CCEEFF">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; background-color: #CCEEFF"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; background-color: #CCEEFF; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="vertical-align: bottom; background-color: #CCEEFF">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; background-color: #CCEEFF">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; background-color: #CCEEFF"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; background-color: #CCEEFF; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,779</FONT></TD>
    <TD STYLE="vertical-align: bottom; background-color: #CCEEFF">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; background-color: #CCEEFF">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; background-color: #CCEEFF"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; background-color: #CCEEFF; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">COSTS AND EXPENSES:</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost of revenue</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,741</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,367</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">86,655</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">81,876</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,120</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24,674</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling, general and administrative</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34,752</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30,215</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,621</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,054</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">126,148</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">112,091</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31,108</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32,728</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating loss</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(118,380</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(112,091</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(27,329</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(32,728</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other income, net</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,722</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,873</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,048</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(116,658</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(110,218</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(27,322</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(31,680</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred stock deemed dividend</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,659</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,404</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss available to common stockholders</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(116,658</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(116,877</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(27,322</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(34,084</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss per common share, basic and diluted</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6.85</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(20.01</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.86</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3.42</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted average common shares outstanding, basic and diluted</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,039,309</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,841,447</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31,756,759</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,952,780</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">See the accompanying notes to the condensed consolidated
financial statements&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; color: #FF9966"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>TONIX PHARMACEUTICALS HOLDING CORP.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONDENSED CONSOLIDATED BALANCE SHEETS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(In Thousands)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="6" CELLPADDING="0" STYLE="width: 80%; font-size: 10pt">
  <TR>
    <TD STYLE="width: 52%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: white 2.25pt solid; width: 22%"><B>December 31, 2023</B></TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="border-left: white 2.25pt solid; border-bottom: Black 1pt solid; width: 22%"><B>December 31, 2022<SUP>1</SUP></B></TD></TR>
  <TR>
    <TD><B>Assets</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD>Cash and cash equivalents&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="border-right: white 2.25pt solid; text-align: right">$&nbsp;&nbsp;24,948</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-left: white 2.25pt solid; text-align: right">$&nbsp;&nbsp;120,229</TD></TR>
  <TR>
    <TD>Inventory</TD>
    <TD STYLE="border-right: white 2.25pt solid; text-align: right">13,639</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-left: white 2.25pt solid; text-align: right">-</TD></TR>
  <TR>
    <TD>Prepaid expenses and other </TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: white 2.25pt solid; text-align: right">9,181</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-left: white 2.25pt solid; border-bottom: Black 1pt solid; text-align: right">10,548</TD></TR>
  <TR>
    <TD>Total current assets</TD>
    <TD STYLE="border-right: white 2.25pt solid; text-align: right">47,768</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-left: white 2.25pt solid; text-align: right">130,777</TD></TR>
  <TR>
    <TD>Other non-current assets</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: white 2.25pt solid; text-align: right">106,689</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-left: white 2.25pt solid; border-bottom: Black 1pt solid; text-align: right">94,913</TD></TR>
  <TR>
    <TD>Total assets</TD>
    <TD STYLE="border-bottom: Black 1.5pt double; border-right: white 2.25pt solid; text-align: right">$&nbsp;&nbsp;154,457</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-left: white 2.25pt solid; border-bottom: Black 1.5pt double; text-align: right">$&nbsp;&nbsp;225,690</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD><B>Liabilities and stockholders' equity</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD>Total liabilities</TD>
    <TD STYLE="border-right: white 2.25pt solid; text-align: right">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;48,932</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-left: white 2.25pt solid; text-align: right">$&nbsp;&nbsp;18,508</TD></TR>
  <TR>
    <TD>Stockholders' equity</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: white 2.25pt solid; text-align: right">105,525</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-left: white 2.25pt solid; border-bottom: Black 1pt solid; text-align: right">207,182</TD></TR>
  <TR>
    <TD>Total liabilities and stockholders' equity</TD>
    <TD STYLE="border-bottom: Black 1.5pt double; border-right: white 2.25pt solid; text-align: right">$&nbsp;&nbsp;&nbsp;154,457</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-left: white 2.25pt solid; border-bottom: Black 1.5pt double; text-align: right">$&nbsp;&nbsp;225,690</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0pt 12pt"><SUP>1</SUP>The condensed consolidated balance sheet for the year
ended December 31, 2022 has been derived from the audited financial statements but do not include all of the information and footnotes
required by accounting principles generally accepted in the United States for complete financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><B>Investor Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Jessica Morris</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Tonix Pharmaceuticals</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Blue"><U>investor.relations@tonixpharma.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(862) 904-8182</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Peter Vozzo</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">ICR Westwicke</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Blue"><U>peter.vozzo@westwicke.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(443) 213-0505</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt"><B>Media Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Ben Shannon</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">ICR Westwicke</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Blue"><U>ben.shannon@westwicke.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(919) 360-3039</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><B>Zembrace&reg; SymTouch&reg; (sumatriptan
Injection): IMPORTANT SAFETY INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt"><B>Zembrace SymTouch (Zembrace) can cause serious side effects,
including heart attack and other heart problems, which may lead to death. Stop use and get emergency help if you have any signs of a heart
attack:</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>discomfort in the center of your chest that lasts for more than a few minutes or goes away and comes back</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>pain or discomfort in your arms, back, neck, jaw or stomach</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>shortness of breath with or without chest discomfort</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>breaking out in a cold sweat</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>nausea or vomiting</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>feeling lightheaded</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt">Zembrace is not for people with risk factors for heart disease
(high blood pressure or cholesterol, smoking, overweight, diabetes, family history of heart disease) unless a heart exam shows no problem.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt">Do not use Zembrace if you have:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>history of heart problems</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>narrowing of blood vessels to your legs, arms, stomach, or kidney (peripheral vascular disease)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>uncontrolled high blood pressure</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>hemiplegic or basilar migraines. If you are not sure if you have these, ask your provider.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>had a stroke, transient ischemic attacks (TIAs), or problems with blood circulation</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>severe liver problems</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>taken any of the following medicines in the last 24 hours: almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, ergotamines,
dihydroergotamine.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="background-color: white">are taking certain antidepressants, known as monoamine oxidase (MAO)-A inhibitors or it has
been 2 weeks or less since you stopped taking a MAO-A inhibitor. Ask your provider for a list of these medicines if you are not sure.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>an allergy to sumatriptan or any of the components of Zembrace</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt">Tell your provider about all of your medical conditions and medicines
you take, including vitamins and supplements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt">Zembrace can cause dizziness, weakness, or drowsiness. If so,
do not drive a car, use machinery, or do anything where you need to be alert.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt">Zembrace may cause serious side effects including:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>changes in color or sensation in your fingers and toes</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>sudden or severe stomach pain, stomach pain after meals, weight loss, nausea or vomiting, constipation or diarrhea, bloody diarrhea,
fever</TD></TR></TABLE>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>cramping and pain in your legs or hips; feeling of heaviness or tightness in your leg muscles; burning or aching pain in your feet
or toes while resting; numbness, tingling, or weakness in your legs; cold feeling or color changes in one or both legs or feet</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>increased blood pressure including a sudden severe increase even if you have no history of high blood pressure</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>medication overuse headaches from using migraine medicine for 10 or more days each month. If your headaches get worse, call your provider.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>serotonin syndrome, a rare but serious problem that can happen in people using Zembrace, especially when used with anti-depressant
medicines called SSRIs or SNRIs. Call your provider right away if you have: mental changes such as seeing things that are not there (hallucinations),
agitation, or coma; fast heartbeat; changes in blood pressure; high body temperature; tight muscles; or trouble walking.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>hives (itchy bumps); swelling of your tongue, mouth, or throat</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>seizures even in people who have never had seizures before</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt"><B>The most common side effects of Zembrace include:</B> pain
and redness at injection site; tingling or numbness in your fingers or toes; dizziness; warm, hot, burning feeling to your face (flushing);
discomfort or stiffness in your neck; feeling weak, drowsy, or tired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt"><FONT STYLE="background-color: white">Tell your provider if you
have any side effect that bothers you or does not go away. These are not all the possible side effects of Zembrace. For more information,
ask your provider.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt">This is the most important information to know about Zembrace
but is not comprehensive. For more information, talk to your provider and read the <FONT STYLE="color: Blue"><U>Patient Information</U></FONT>
and <FONT STYLE="color: Blue"><U>Instructions for Use</U></FONT>. You can also visit <FONT STYLE="color: Blue"><U>www.upsher-smith.com</U></FONT>
or call 1-888-650-3789.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt">You are encouraged to report adverse effects of prescription
drugs to the FDA. Visit <FONT STYLE="color: Blue"><U>www.fda.gov/medwatch</U></FONT>, or call
1-800-FDA-1088.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-bottom: 0; margin-left: 0"><B>INDICATION AND USAGE<BR>
</B><BR>
Zembrace is a prescription medicine used to treat acute migraine headaches with or without aura in adults who have been diagnosed with
migraine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-bottom: 0; margin-left: 0">Zembrace is not used to prevent
migraines. It is not known if it is safe and effective in children under 18 years of age.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 4pt 0 8pt"><B>Tosymra&reg; (sumatriptan nasal spray): IMPORTANT SAFETY INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt"><B>Tosymra can cause serious side effects, including heart attack
and other heart problems, which may lead to death. Stop Tosymra and get emergency medical help if you have any signs of heart attack</B>:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 19.7pt"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #404040">&middot;</FONT></TD><TD>discomfort in the center of your chest that lasts for more than a few minutes or goes away and comes back</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 19.7pt"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #404040">&middot;</FONT></TD><TD>severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 19.7pt"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #404040">&middot;</FONT></TD><TD>pain or discomfort in your arms, back, neck, jaw, or stomach</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 19.7pt"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #404040">&middot;</FONT></TD><TD>shortness of breath with or without chest discomfort</TD></TR></TABLE>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 19.7pt"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #404040">&middot;</FONT></TD><TD>breaking out in a cold sweat</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 19.7pt"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #404040">&middot;</FONT></TD><TD>nausea or vomiting</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 19.7pt"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #404040">&middot;</FONT></TD><TD>feeling lightheaded</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt">Tosymra is not for people with risk factors for heart disease (high
blood pressure or cholesterol, smoking, overweight, diabetes, family history of heart disease) unless a heart exam is done and shows no
problem.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt">Do not use Tosymra if you have:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #404040">&middot;</FONT></TD><TD>history of heart problems</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #404040">&middot;</FONT></TD><TD>narrowing of blood vessels to your legs, arms, stomach, or kidney (peripheral vascular disease)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #404040">&middot;</FONT></TD><TD>uncontrolled high blood pressure</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #404040">&middot;</FONT></TD><TD>severe liver problems</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #404040">&middot;</FONT></TD><TD>hemiplegic or basilar migraines. If you are not sure if you have these, ask your healthcare provider.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #404040">&middot;</FONT></TD><TD>had a stroke, transient ischemic attacks (TIAs), or problems with blood circulation</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #404040">&middot;</FONT></TD><TD>taken any of the following medicines in the last 24 hours: almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, ergotamines,
or dihydroergotamine. Ask your provider if you are not sure if your medicine is listed above.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #404040">&middot;</FONT></TD><TD>are taking certain antidepressants, known as monoamine oxidase (MAO)-A inhibitors or it has been 2 weeks or less since you stopped
taking a MAO-A inhibitor. Ask your provider for a list of these medicines if you are not sure.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #404040">&middot;</FONT></TD><TD>an allergy to sumatriptan or any ingredient in Tosymra</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Tell your provider about all of your medical conditions and medicines you
take, including vitamins and supplements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Tosymra can cause dizziness, weakness, or drowsiness. If so, do not drive
a car, use machinery, or do anything where you need to be alert.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Tosymra may cause serious side effects including:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #404040">&middot;</FONT></TD><TD>changes in color or sensation in your fingers and toes</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #404040">&middot;</FONT></TD><TD>sudden or severe stomach pain, stomach pain after meals, weight loss, nausea or vomiting, constipation or diarrhea, bloody diarrhea,
fever</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #404040">&middot;</FONT></TD><TD>cramping and pain in your legs or hips, feeling of heaviness or tightness in your leg muscles, burning or aching pain in your feet
or toes while resting, numbness, tingling, or weakness in your legs, cold feeling or color changes in one or both legs or feet</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #404040">&middot;</FONT></TD><TD>increased blood pressure including a sudden severe increase even if you have no history of high blood pressure</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #404040">&middot;</FONT></TD><TD>medication overuse headaches from using migraine medicine for 10 or more days each month. <B>If your headaches get worse, call your
provider</B>.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #404040">&middot;</FONT></TD><TD>serotonin syndrome, a rare but serious problem that can happen in people using Tosymra, especially when used with anti-depressant
medicines called SSRIs or SNRIs. <B>Call your provider right away if you have</B>: mental changes such as seeing things that are not there
(hallucinations), agitation, or coma; fast heartbeat; changes in blood pressure; high body temperature; tight muscles; or trouble walking.</TD></TR></TABLE>


<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #404040">&middot;</FONT></TD><TD>hives (itchy bumps); swelling of your tongue, mouth, or throat</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #404040">&middot;</FONT></TD><TD>seizures even in people who have never had seizures before</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>The most common side effects of Tosymra include</B>: tingling, dizziness,
feeling warm or hot, burning feeling, feeling of heaviness, feeling of pressure, flushing, feeling of tightness, numbness, application
site (nasal) reactions, abnormal taste, and throat irritation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Tell your provider if you have any side effect that bothers you or does
not go away. These are not all the possible side effects of Tosymra. For more information, ask your provider.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">This is the most important information to know about Tosymra but is not
comprehensive. For more information, talk to your provider and read the <FONT STYLE="color: Blue"><U>Patient Information</U></FONT> and
<FONT STYLE="color: Blue"><U>Instructions for Use</U></FONT>. You can also visit <FONT STYLE="color: Blue"><U>www.upsher-smith.com</U></FONT>
or call 1-888-650-3789.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">You are encouraged to report negative side effects of prescription drugs
to the FDA. Visit <FONT STYLE="color: Blue"><U>www.fda.gov/medwatch,</U></FONT> or call 1-800-FDA-1088.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>INDICATION AND USAGE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Tosymra is a prescription medicine used to treat acute migraine headaches
with or without aura in adults.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Tosymra is not used to treat other types of headaches such as hemiplegic
or basilar migraines or cluster headaches.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Tosymra is not used to prevent migraines. It is not known if Tosymra is
safe and effective in children under 18 years of age.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 16; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>tnxp-20240401.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +6spw7xRiXhun8uCbn1MSaWMSbP9w5dzSelBtm98HZmKzyEnarfh5yQaf4EmkXIA -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:TNXP="http://TNXP/20240401" elementFormDefault="qualified" targetNamespace="http://TNXP/20240401">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://TNXP/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="tnxp-20240401_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="tnxp-20240401_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>tnxp-20240401_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>tnxp-20240401_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://TNXP/role/Cover" xlink:href="tnxp-20240401.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://TNXP/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139958176125264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Apr. 01, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Apr.  01,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">TONIX PHARMACEUTICALS HOLDING CORP.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001430306<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-1434750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">26 Main Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Chatham<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07928<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(862)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">904-8182<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TNXP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( &:$@5@'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " !FA(%8'#D.<>\    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+/
M2L0P$(=?17)O)VU5,'1[V<63@N""XBTDL[MAFS\D(^V^O6G=[2+Z $(NF?GE
MFV\@K0I"^8@OT0>,9##=C+9W2:BP8@>B( "2.J"5J<P)EYL['ZVD?(U["%(=
MY1ZAYOP>+)+4DB1,P"(L1-:U6@D549*/9[Q6"SY\QGZ&:078HT5'":JR M9-
M$\-I[%NX B888;3INX!Z(<[5/[%S!]@Y.2:SI(9A*(=FSN4=*GA_?GJ=URV,
M2R2=POPJ&4&G@"MVF?S6K#?;1];5O+XM>#[5MN:BN1/\X6-R_>%W%;9>FYWY
MQ\87P:Z%7_^B^P)02P,$%     @ 9H2!6)E<G",0!@  G"<  !,   !X;"]T
M:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M
M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R
M>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2P]R"BPA+>!3+
MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!
M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K
MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2
MBW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K
M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
M" !FA(%8!R\D.D0$  !L$   &    'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;)V8;7/B-A#'OXK&G>G<S83X 4)("LPX)+G02\ -W,.TTQ?"%E@36W)E$<*W
M[\H0F]Z9-=,WP;*]?_^\6O]72G\CU4L>,Z;)6YJ(?&#%6F?7MIV',4MI?BXS
M)N#*4JJ4:ABJE9UGBM&H"$H3VW.<KIU2+JQAOS@7J&%?KG7"!0L4R==I2M7V
MAB5R,[!<Z_W$,U_%VIRPA_V,KMB,Z2]9H&!DERH13YG(N11$L>7 \MWK&Z]C
M HH[OG*VR0^.B7F5A90O9C".!I9CB%C"0FTD*/R\LA%+$J,$'/_L1:WRF2;P
M\/A=_;YX>7B9!<W92";?>*3C@=6S2,26=)WH9[EY8/L7NC!ZH4SRXB_9[.[M
M="P2KG,MTWTP$*1<['[IVSX1!P'M[I$ ;Q_@%=R[!Q64MU3385_)#5'F;E S
M!\6K%M$ QX69E9E6<)5#G!Z.Y"M3?5N#E#EAA_NPFUV8=R3,S]0Y<=PSXCE>
MY[_A-A"4&%Z)X15Z;0R#_.4O<JU@HOZN(]HI=.H53/5>YQD-V<""\LR9>F76
M\-=?W*[S&\+7+OG:F/KP5H9KJ$5-YMN,U<'AX;W69P2B4T)T4!4?"**"XCZA
MJSH*/'Y)DYPA'!<EQ\5IR0B8XC(B=R(B4'RU><&5BC(JZJBID+HE6Q=5O!.:
MZRVYYPDCDW6ZJ"]N7,-QW%:[Z[A7",]ER7-Y"L\S6W%3VI"T"4UK,X7KS*>3
M\7<2//C/3_[H[LM\//(?9^1A^G@[GGPBH^ES<([0]DK:WBFT(YA<11,R%A%[
M(Y_9MHX75W(@B9VVTW:Z"-95B75U"M:<OI%Q!&Q\R4-:F/KQ*<85O6X+\#J7
M%PZ"YSJ5B3JG (Y%*%4F5<%V1F8:/@HB%1G)-204\BJCVJEO4)]\Q2 /G-X]
M!=*/(O#'_.S]@#S"?60JZLEP2:]+GJ#SPYLJ:$ 89=4(7-3'?Z(<F1'D<"XW
MHI80EQO%5,<TQ="J'N#B+OXC6CF_@9*O7(3U&<0U)[]C:%5G<'%K_Q$MD+F&
M#_A/GATO.ES1N;SR>AA;U2U<W.2+&?1AR7@<!1?XT.MZ'S&4JCFXN+,_RA"R
M$L128-VA0>3*Z;1Z;L_#B*KVX.*^_DUQK9F U*3I6NQM+:^EPH6:FKM;]0 7
MM^Z93'C(-1<K^+@UM'B:U/+@*HT\E?F[N%<'BK5"2 ^#+VRW!H-E$*P6I\OE
MD?G#]9K(O,KV/=R8?R(;Y_D:R)H &V0; 2O+]W!_GG,-ZR"Y)*[W8?&1S%BX
MAGJK;><-2J8^I3%Z&;Y@: <+?MR8YXI&IL1FVW0A:PNL26#R/<!(*EOW< M^
MSPJY>PMC*E;LZ!*M06CBSV[]/S"FRL^]D_S\+F5J9;+T"11T;%PBHZ)^_O[G
MVM\^V#N:??@3-4_,2<*6(.2<7X(WJ]W6=C?0,BNVDPNI87-:',:,0KV;&^#Z
M4DK]/C [U/(?#,-_ 5!+ P04    " !FA(%8GZ ;\+$"  #B#   #0   'AL
M+W-T>6QE<RYX;6S=5VUKVS 0_BM"/V!N8FKBD1BV0&&PC4+S85^56'8$>O%D
MN7/ZZZ>S;"=I=67=A['-H<G=/;J[1W<GF:Y;=Y+\X<BY([V2NMW0HW/-^R1I
M#T>N6/O.-%Q[I#)6,>=56R=M8SDK6W!2,EG>W&2)8D+38JT[=:=<2PZFTVY#
M;VA2K"NCSY:4!H-?RA0GCTQNZ)9)L;=B6,N4D*=@7H+A8*2QQ'DJ?$,78&F?
M KP(&K <XRBAC05C$C*$[_VX_!DP::U7A90SP24-AF+=,.>XU7=>&18/QA<0
M&>7=J?$,:\M.B^4M/3L,/S[)WMB2VSG-@DZF8BUY!72LJ(_PZTR3 .B<45XH
M!:N-9@.'R6,4?-@#E_(!6OBMNHK=5R3TXE,);2"PU4GTA$8QA D*Q+^,%F)?
MA+W]K;"D$8_&?>S\;O2@?^^,X_>65Z(?]+Z:\V/1%WATUC3R]$&*6BL>]O[+
M"8LUF_S(T5CQY+/!I!R\@5M*'KEUXG!I^6%9L^.]FZ:IKW#.RW^0\Y^M<\TU
MMTQ>DO:C_S=7^2V,D_'T7!S1JP,Z6PE<A!OZ%>Y7>>9 ]IV03NA1.XJRY/K%
M.?7A'=O["_PJOE]?\HIUTNUF<$//\A=>BD[E\ZI[J,NXZBQ_AOMHD<VWL,\E
M=,E[7FY'U=;[021>\%G'!QR>(W?#$T<PGX#%$<"P/!@#S"=X87G^I_VLT/T$
M#..VBB(KU&>%^@2O&+(=/EB>N$_NG_A.\SQ-LPRKZ'8;9;#%ZI9E\!>/AG$#
M#RP/9'I;K?%NXQ/R^AQ@/7UM0K"=XI.([12O-2#QNH%'GL>[C>4!#ZP+V.Q
M_G@>F*FX3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X %F>0IA@"
MIQ%', ;  4/2='@//GL?)=-[*CG_5U/\!%!+ P04    " !FA(%8EXJ[',
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MZ8Y>9WK_,'G4'EKG5LJ]AU>RY1AQ_)[E#U!+ P04    " !FA(%8)!Z;HJT
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M2P$"% ,4    " !FA(%8!T%-8H$   "Q    $               @ $
M9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( &:$@5@<.0YQ[P   "L"   1
M              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    (
M &:$@5B97)PC$ 8  )PG   3              "  <T!  !X;"]T:&5M92]T
M:&5M93$N>&UL4$L! A0#%     @ 9H2!6 <O)#I$!   ;!   !@
M     ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    (
M &:$@5B?H!OPL0(  .(,   -              "  8@,  !X;"]S='EL97,N
M>&UL4$L! A0#%     @ 9H2!6)>*NQS     $P(   L              ( !
M9 \  %]R96QS+RYR96QS4$L! A0#%     @ 9H2!6*K$(A8S 0  (@(   \
M             ( !31   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( &:$
M@5@D'INBK0   /@!   :              "  :T1  !X;"]?<F5L<R]W;W)K
M8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( &:$@5AED'F2&0$  ,\#   3
M          "  9(2  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D
*/@(  -P3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tnxp_8k-040124.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://TNXP/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>tnxp-20240401.xsd</File>
    <File>tnxp-20240401_lab.xml</File>
    <File>tnxp-20240401_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="tnxp_8k-040124.htm">tnxp_8k-040124.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tnxp_8k-040124.htm": {
   "nsprefix": "TNXP",
   "nsuri": "http://TNXP/20240401",
   "dts": {
    "schema": {
     "local": [
      "tnxp-20240401.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "tnxp-20240401_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "tnxp-20240401_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tnxp_8k-040124.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "report": {
    "R1": {
     "role": "http://TNXP/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2024-04-01",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tnxp_8k-040124.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-04-01",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tnxp_8k-040124.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Extension",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001999371-24-004298-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001999371-24-004298-xbrl.zip
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MD8<A1DXVD-\3?7H&A@E!ZZU<'!ZONFA;' :8*5%#I&*>NF"V3I8 Q/QPJ'3
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M]!QFG7HUCK?V0^'FM&IUSH\IT42T[]3JQ=Y<:QZSG'4,IO*WF<=]?("% _6
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MDIR9^"*^FA(,/;C"!_59Z<2^L2BT*K#'%*#RQEX %.?# 6@?TD2QHJH!7XA
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M3?-6:>2QS "FB/:+->.F4]T<V*/C1DHD=](7*ML"5W0:JINXGU,:+FVOIX/
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M=Z/86JQ@H9KGO3:8QBL\[5X!$CA@*5L8)@\<V^M$'XA021\IWM'M4)K4,*>
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M$;WO:$7TOJD5T7N/K8AOE::6+8EO&W_S:TW$2N5G=2=2GH_L<:R57#IT<PB
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M"@FIOX0/9$%8!!^[F7,)BM="3S(H-M  K> $\IT1>W&50^&K-0-,A#V","[
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M ]$HM*@0>R+BUZT\8R>"[GNA:"E=<P%8-=$P9$'18?<& E+)_3*R%)BEB1K
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M7M]T+3_)S7J3_&N%4R*W_!=02P,$%     @ 9X2!6$]#DQ%2!P  Q5<  !4
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MG\\GIAPFZ@(5IJ%PBB3)B<?[N[8Z(",<HP9SL*&2Q22=&L/-^/GH K1KZS0
MRI_,B203:ZAA5%M.\ -G$NY@ -0)!4V[H,X<E#(SI<C9;7RX$(L)TTVP,N<9
M5D@>KUIW2W G''X)FG!L;+">:8^P RKDF-(Q28DI&1^2&"-J !%\CO?-EU?Q
MY&))>8YG33G!E?+A+F8+B6MD1=QSFC  ,Y3D'- FO8UH,PD8G0..6:R/L;4
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M8X.Z\@1?617BB& VMDG1\ZD"@,Q1S8<"^#FN<.2N>V["[RU>P.Q)8!D#5HF
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M8:*=%M;<2%EQHZ;(VZIN4A?N3P_M']/^/:E\J\AO\B>W$7(9I5.GP!D= >Q
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M>7A^7>J#UF=C40RZX>R$G?Y/K:[NG30*Y9%Y8 &O @.')TO7>T\O?D4Z^PK
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M^-K:XG\!4$L! A0#%     @ 9X2!6)DW"W[=2@  A@$"  L
M ( !     &5X.3DM,#$N:'1M4$L! A0#%     @ 9X2!6),VX,LE P  RPL
M !$              ( !!DL  '1N>' M,C R-# T,#$N>'-D4$L! A0#%
M  @ 9X2!6*%$FA_]"@  @(8  !4              ( !6DX  '1N>' M,C R
M-# T,#%?;&%B+GAM;%!+ 0(4 Q0    ( &>$@5A/0Y,14@<  ,57   5
M          "  8I9  !T;GAP+3(P,C0P-# Q7W!R92YX;6Q02P$"% ,4
M" !GA(%8\31-RS81  "/6@  $@              @ $/80  =&YX<%\X:RTP
?-# Q,C0N:'1M4$L%!@     %  4 /@$  '5R      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>tnxp_8k-040124_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="tnxp-20240401.xsd" xlink:type="simple"/>
    <context id="AsOf2024-04-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-01</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2024-04-01" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2024-04-01" id="Fact000004">0001430306</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2024-04-01" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2024-04-01" id="Fact000010">2024-04-01</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2024-04-01" id="Fact000011">TONIX PHARMACEUTICALS HOLDING CORP.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2024-04-01" id="Fact000012">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2024-04-01" id="Fact000013">001-36019</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2024-04-01" id="Fact000014">26-1434750</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2024-04-01" id="Fact000015">26 Main Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="AsOf2024-04-01" id="Fact000016">Chatham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2024-04-01" id="Fact000017">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2024-04-01" id="Fact000018">07928</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2024-04-01" id="Fact000019">(862)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2024-04-01" id="Fact000020">904-8182</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2024-04-01" id="Fact000021">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2024-04-01" id="Fact000022">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2024-04-01" id="Fact000023">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2024-04-01" id="Fact000024">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2024-04-01" id="Fact000025">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2024-04-01" id="Fact000026">TNXP</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2024-04-01" id="Fact000027">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2024-04-01" id="Fact000028">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
